Atavistik Bio Announces Nomination of Precision Oncology Development Candidate, ATV-1601, a Selective Allosteric AKT1 E17K Small Molecule Inhibitor Portfolio News / By Karina Tin October 15, 2024 Atavistik Bio Announces Nomination of Precision Oncology Development Candidate, ATV-1601, a Selective Allosteric AKT1 E17K Small Molecule Inhibitor Read More »
Circle Pharma and Boehringer Ingelheim announce new research collaboration to develop a novel precision cancer treatment Portfolio News / By Karina Tin October 9, 2024 Circle Pharma and Boehringer Ingelheim announce new research collaboration to develop a novel precision cancer treatment Read More »
Judo Bio Unveils Data Demonstrating Receptor-mediated Delivery of Oligonucleotides to the Kidney Portfolio News / By Karina Tin October 7, 2024 Judo Bio Unveils Data Demonstrating Receptor-mediated Delivery of Oligonucleotides to the Kidney Read More »
Judo Bio Launches with $100 Million Financing to Develop Oligonucleotide Therapies Delivered to the Kidney and Appoints Rajiv Patni as CEO Portfolio News / By Karina Tin October 7, 2024 Judo Bio Launches with $100 Million Financing to Develop Oligonucleotide Therapies Delivered to the Kidney and Appoints Rajiv Patni as CEO Read More »
Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration Portfolio News / By Karina Tin September 24, 2024 Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration Read More »
Nura Bio Closes Series A Financing with $68 Million in New Funds, Bringing Total Raised to $140+ Million Portfolio News / By Karina Tin September 17, 2024 Nura Bio Closes Series A Financing with $68 Million in New Funds, Bringing Total Raised to $140+ Million Read More »
Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate Portfolio News / By Karina Tin September 10, 2024 Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate Read More »
Kallyope Announces License Agreement with Novo Nordisk Portfolio News / By Karina Tin September 10, 2024 Kallyope Announces License Agreement with Novo Nordisk Read More »
Synthekine Granted U.S. FDA Fast Track Designation for CD19 CAR-T and Orthogonal IL-2 Investigational Therapy, SYNCAR-001 + STK-009, for the Treatment of Lupus Without Lymphodepletion Portfolio News / By Karina Tin September 4, 2024 Synthekine Granted U.S. FDA Fast Track Designation for CD19 CAR-T and Orthogonal IL-2 Investigational Therapy, SYNCAR-001 + STK-009, for the Treatment of Lupus Without Lymphodepletion Read More »
Circle Pharma Closes $90 Million Series D Financing to Advance Innovative Oral Macrocycle Therapies Portfolio News / By Karina Tin September 3, 2024 Circle Pharma Closes $90 Million Series D Financing to Advance Innovative Oral Macrocycle Therapies Read More »
